Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the fifteen brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and fourteen have issued a buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $21.33.
A number of equities analysts recently issued reports on ORIC shares. JPMorgan Chase & Co. raised their price target on Oric Pharmaceuticals from $23.00 to $26.00 and gave the stock an "overweight" rating in a report on Wednesday, October 14th. Stifel Nicolaus boosted their price target on Oric Pharmaceuticals from $14.00 to $18.00 and gave the company a "buy" rating in a research report on Monday, October 26th. Citigroup upped their price objective on Oric Pharmaceuticals from $16.00 to $17.00 and gave the company a "buy" rating in a research note on Tuesday. BTIG Research reaffirmed a "buy" rating and set a $26.00 price objective on shares of Oric Pharmaceuticals in a research report on Tuesday. Finally, Leerink Partners assumed coverage on Oric Pharmaceuticals in a research report on Monday, October 5th. They set an "outperform" rating and a $26.00 price objective for the company.
Get Our Latest Research Report on ORIC
Oric Pharmaceuticals Price Performance
Shares of NASDAQ:ORIC opened at $8.00 on Wednesday. Oric Pharmaceuticals has a 1-year low of $7.23 and a 1-year high of $14.68. The stock has a market cap of $829.20 million, a P/E ratio of -5.48 and a beta of 1.23. The firm has a fifty day moving average price of $11.36 and a 200 day moving average price of $10.98.
Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its quarterly earnings data on Monday, November 16th. The company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.05). Sell-side analysts expect that Oric Pharmaceuticals will post -1.53 EPS for the current fiscal year.
Insider Activity
In other news, CFO Dominic Piscitelli sold 77,000 shares of the company's stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $13.69, for a total transaction of $1,054,130.00. Following the completion of the sale, the chief financial officer owned 69,828 shares in the company, valued at $955,945.32. This represents a 52.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 105,000 shares of company stock valued at $1,432,952 over the last quarter. Insiders own 5.70% of the company's stock.
Hedge Funds Weigh In On Oric Pharmaceuticals
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in Oric Pharmaceuticals in the second quarter valued at about $73,904,000. Siren L.L.C. boosted its holdings in Oric Pharmaceuticals by 197.6% in the 1st quarter. Siren L.L.C. now owns 2,998,192 shares of the company's stock valued at $37,987,000 after purchasing an additional 1,990,617 shares in the last quarter. Algert Global LLC boosted its holdings in Oric Pharmaceuticals by 791.3% in the 2nd quarter. Algert Global LLC now owns 1,215,293 shares of the company's stock valued at $13,162,000 after purchasing an additional 1,078,943 shares in the last quarter. Bank of America Corp DE acquired a new position in Oric Pharmaceuticals during the 2nd quarter worth approximately $11,675,000. Finally, Defilade Capital Management L.P. acquired a new position in Oric Pharmaceuticals during the 1st quarter worth approximately $10,680,000. 95.05% of the stock is currently owned by hedge funds and other institutional investors.
Top Oric Pharmaceuticals Stories
These are some of the ORIC stories that stood out recently:
- Positive Sentiment: ORIC said it initiated the global Phase 3 Himalayas-1 trial of rinzimetostat in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone. The trial is supported by a clinical collaboration and drug-supply agreement with Bayer, marking progress in the company’s clinical pipeline. ORIC third-quarter results and program updates
- Positive Sentiment: BTIG reaffirmed its Buy rating and $26 price target. Citigroup also maintained a Buy rating and raised its target to $17 from $16. The endorsements and higher target suggest analysts see substantial potential upside. BTIG reiterates Buy rating
- Negative Sentiment: ORIC reported a third-quarter loss of $0.44 per share, wider than analysts’ expected loss of $0.39. Reports also highlighted increased spending as the company advances Phase 3 programs, which may weigh on results as development continues. ORIC Q3 2026 earnings
Oric Pharmaceuticals Company Profile
(
Get Free Report)
Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat. The company's drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oric Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oric Pharmaceuticals wasn't on the list.
While Oric Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.